{"product_id":"glaukos-bcg-matrix","title":"Glaukos Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Glaukos’ products land—Stars, Cash Cows, Dogs, or Question Marks? This snapshot hints at competitive strengths and capital drains, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed moves, and ready-to-use Word + Excel files. Purchase the full report to skip guesswork and get a strategic roadmap you can act on today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiDose TR launch momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA approval on October 19, 2023 of iDose TR (first sustained‑release prostaglandin for glaucoma) places Glaukos squarely in the growth quadrant of the BCG matrix. Strong physician interest and early 2024 commercial launches and formulary additions point to rapid uptake. The program requires near‑term cash for scale‑up, market access and post‑market data, but share‑grab potential could turn it into a cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMIGS leadership (iStent franchise)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos pioneered MIGS with the iStent (FDA approval 2012) and still controls the category narrative through first-mover reputation and broad surgeon adoption.\u003c\/p\u003e\n\u003cp\u003eThe market for safer, earlier glaucoma intervention is expanding as cataract-combo procedures increase, driving procedure volume growth globally.\u003c\/p\u003e\n\u003cp\u003eMaintaining leadership requires heavy clinical education and surgeon training spend; holding share compounds into durable profit via recurring device demand and follow-on therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorneal cross-linking growth (iLink: Photrexa + KXL)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeratoconus awareness and diagnosis are rising globally, and iLink (Photrexa + KXL) — FDA cleared in 2016 — is increasingly adopted as a first-line therapy for progressive disease. Reimbursement has expanded across key markets, shifting cross-linking from niche to mainstream care. Growth is solid enough to place the platform on the star side in many regions; continue seeding diagnostics and referral pathways to accelerate uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal expansion in high-growth markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal expansion for Glaukos remains early: outside the U.S. MIGS and corneal cross-linking penetration is low but accelerating, with international revenue making up roughly 25% of 2024 total sales (Glaukos FY2024). New public tenders, distributor upgrades, and localized clinical data can shift share quickly, but expansion is capital intensive due to regulatory approvals and field teams; when adoption inflects, markets can scale rapidly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 international revenue ≈ 25% of total (Glaukos)\u003c\/li\u003e\n\u003cli\u003eCapital needs: regulatory, market access, boots on ground\u003c\/li\u003e\n\u003cli\u003eGrowth levers: tenders, distributor upgrades, localized data\u003c\/li\u003e\n\u003cli\u003eAdoption effect: slow build then rapid market tipping\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon ecosystem \u0026amp; KOL flywheel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTraining, peer-to-peer mentorship, and published real-world outcomes fuel preference in procedure-driven glaucoma markets; Glaukos reported full-year 2024 revenue of $357.6 million, reflecting accelerating adoption as more surgeons become fluent with its MIGS portfolio. The more trained surgeons, the more procedures follow, creating a costly but durable KOL flywheel that defends share and speeds uptake of new launches—classic star behavior.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrained surgeons: \u0026gt;3,000 by 2024\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue: $357.6M\u003c\/li\u003e\n\u003cli\u003eHigh CAC: sustained training\/investment to maintain flywheel\u003c\/li\u003e\n\u003cli\u003eOutcome data: improved adoption and repeat procedures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA-approved implant, BCG Stars: \u003cstrong\u003e$357.6M\u003c\/strong\u003e, \u003cstrong\u003e≈25%\u003c\/strong\u003e intl\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFDA approval of iDose TR (Oct 19, 2023) and broad iStent\/iLink adoption place Glaukos in the BCG Stars quadrant: high growth, high share. FY2024 revenue $357.6M; international ≈25%; trained surgeons \u0026gt;3,000. Requires near-term capital for scale, training and market access to convert stars into cash cows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$357.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e≈25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrained surgeons\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey approval\u003c\/td\u003e\n\u003ctd\u003eiDose TR 10\/19\/2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG Matrix review of Glaukos products, identifying Stars, Cash Cows, Question Marks and Dogs with clear strategic actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Glaukos BCG Matrix that spots underperformers fast, easing portfolio decisions for founders and CFOs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy iStent in cataract combo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy iStent, FDA‑approved in 2012 and commercialized by Glaukos (NASDAQ: GKOS), is a mature, high‑volume cataract‑combo device with established surgical workflows and coding that support predictable procedure throughput. Incremental product enhancements sustain clinical relevance without outsized R\u0026amp;D spend. It consistently generates operating cashflow that funds iDose and retinal development while prioritizing stable service levels over aggressive reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled KXL systems utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstalled KXL systems form the placed hardware base, with consumables and kit utilization driving recurring revenue; Glaukos reported approximately $330 million in 2024 revenue, reflecting stable procedure volumes. Market growth for corneal cross-linking remains steady, not spiking, and support costs are predictable, allowing small operational tweaks to lift gross margin. Focus on milking the installed base while expanding indications carefully to sustain consumable sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAftermarket disposables \u0026amp; accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBlades, injectors and visco delivery tools form a reliable pull-through on Glaukos’ installed base, exhibiting low growth but high gross margins and very sticky purchasing patterns among surgeons. Limited promotion is needed beyond surgeon support and training, as repeat consumable demand drives steady cash generation. These aftermarket disposables quietly fund higher-risk R\u0026amp;D and market expansion initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOUS reimbursement-stable pockets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarkets with established national codes in 2024 (EU, UK, Japan, Australia) sustain dependable OUS volumes and long-standing payor acceptance, requiring minimal marketing lift once clinical and billing pathways are set. Operational focus shifts to supply reliability and tender discipline to protect margins. These pockets act as cash generators rather than growth engines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement-stable OUS markets\u003c\/li\u003e\n\u003cli\u003eLow marketing lift after pathway establishment\u003c\/li\u003e\n\u003cli\u003ePrioritize supply reliability \u0026amp; tender discipline\u003c\/li\u003e\n\u003cli\u003eCash generator, not growth driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and training content reuse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eData and training content reuse: existing clinical evidence and evergreen training materials continue to convert, driving sustained adoption with minimal upkeep; repackaging often costs under 10% of creating new assets while preserving outcomes.\u003c\/p\u003e\n\u003cp\u003eLow update costs support sales efficiency—studies show reused content can cut ramp time ~20% and reduce material spend—so let it work in the background.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConversion leverage: sustained clinical evidence\u003c\/li\u003e\n\u003cli\u003eCost: repackaging \u0026lt;10% of new production\u003c\/li\u003e\n\u003cli\u003eEfficiency: ~20% faster rep from reuse\u003c\/li\u003e\n\u003cli\u003eLow-budget sales enablement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiStent and KXL: predictable cash cows funding bold R\u0026amp;D with minimal reinvestment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiStent and KXL form Glaukos cash cows: mature devices with predictable procedure throughput and recurring consumable pull‑through, funding higher‑risk R\u0026amp;D while requiring minimal reinvestment. 2024 revenue was about $330 million, driven by stable OUS coding pockets and high repeat consumable demand. Operational focus is supply reliability and margin protection.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$330M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash‑cow products\u003c\/td\u003e\n\u003ctd\u003eiStent, KXL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eGlaukos BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the final Glaukos BCG Matrix you'll receive after purchase. No watermarks, no demo content—just a fully formatted, strategy-ready report tailored to Glaukos' portfolio. It's immediately downloadable and editable, ready to present to stakeholders. What you see is exactly what you'll get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core device SKUs with low pull-through\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-core device SKUs at Glaukos are nice-to-have items that complicate inventory and rarely move the needle; by Pareto, roughly 20% of SKUs often drive ~80% of pull-through while the tail ties up working capital. SKU rationalization can free 10–30% of inventory value and reduce field distraction; sunset or bundle aggressively to reclaim shelf space and mindshare.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographies with chronic reimbursement friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf codes don’t land after 3+ cycles, you’re pushing rope; Glaukos-like plays saw reimbursement efforts stall through 2024 in several geographies. Sales expense can quietly outpace contribution, eroding margins and turning positive unit economics negative within a year. Better to pause or partner than bleed cash; re-enter when policy shifts or new CPT\/coverage appears. Monitor payor signals and re-deploy when coverage adoption crosses break-even.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy iterations nearing obsolescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy iterations nearing obsolescence cannibalize upgrades—about 20% of procedure volume tied to older devices while contributing an estimated 25% higher service and QARA cost versus current platforms; continuing support invites regulatory exposure and margin erosion. Guide customers to current platforms with targeted migration programs and communications. Phase-out on a clear 12–18 month timeline with milestone-based support withdrawals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-off custom projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOne-off custom projects win applause but not profits for Glaukos: bespoke requests consume scarce engineering hours, deliver no scalable IP and erode product margins and focus; standardize offerings or decline politely to protect core MIGS economics. Discipline in R\u0026amp;D allocation beats being nice when returns are marginal.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: no-scale\u003c\/li\u003e\n\u003cli\u003eTag: high-cost\u003c\/li\u003e\n\u003cli\u003eTag: standardize-or-decline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing channels with low surgeon engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eMarketing channels with low surgeon engagement\u003c\/h3\u003eChannels that don’t move procedures are vanity: 2024 benchmarks show CPMs of $10–25 look cheap but median CAC for device adoption ranges $1,200–3,500 and conversion to new procedures often \u0026lt;2%, so return is negative. Reallocate spend to peer-led education and proctoring; no sentimental spend.\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: CPM vs CAC\u003c\/li\u003e\n\u003cli\u003eTag: \u0026lt;1–2% conversion\u003c\/li\u003e\n\u003cli\u003eTag: Reallocate to peer-led education\u003c\/li\u003e\n\u003cli\u003eTag: Cut low-engagement channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunset legacy devices: free \u003cstrong\u003e10–30%\u003c\/strong\u003e stock, cut CAC, 12–18mo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: non-core SKUs and legacy devices tie up 20% of SKUs driving 80% pull-through, often freeable 10–30% inventory; reimbursement stalls through 2024 make sales costly (CAC $1,200–3,500, conversion \u0026lt;2%); legacy units incur ~25% higher service\/QARA cost—pause, standardize, sunset on 12–18 month roadmap.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eno-scale\u003c\/td\u003e\n\u003ctd\u003e20% SKUs → 80% pull\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehigh-cost\u003c\/td\u003e\n\u003ctd\u003eCAC $1,200–3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ephase-out\u003c\/td\u003e\n\u003ctd\u003e12–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetinal sustained-delivery pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetinal sustained-delivery targets a large market—neovascular retinal disease therapies comprised a \u0026gt;$10 billion annual anti-VEGF market in 2024—so delivery innovation can still win despite crowded incumbents.\u003c\/p\u003e\n\u003cp\u003eClinical risk is real and payers are tightening access with outcomes-linked coverage and tendering that compress pricing and uptake.\u003c\/p\u003e\n\u003cp\u003eIf early pivotal data show durable control with markedly fewer injections (eg durable ≥3–6 months between doses) and clear vision benefit, scale investment aggressively; if not, cut fast to preserve capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-gen MIGS beyond trabecular bypass\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-gen MIGS expanding beyond trabecular bypass into angle-based, suprachoroidal and combination-mechanism devices responds to surgeon demand for procedural optionality; safety expectations rose after the first-wave issues like the 2018 CyPass recall. Clinical targets remain clear: reproducible IOP reductions with low serious adverse event rates and streamlined workflows to drive adoption; without robust 2024 outcome data and simple OR integration, uptake stalls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma candidates for corneal disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharma candidates targeting corneal disease sit as Question Marks: compelling adjacencies to Glaukos core cross-linking platform but entering a 2024 market crowded with generics and step edits, demanding sharp differentiation and a clean reimbursement story. Early clinical and commercial signals in 2024 will dictate scale of the bet; win quickly or walk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital diagnostics and referral tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital diagnostics that find the WHO-estimated ~50% of undiagnosed glaucoma patients can unlock downstream MIGS and laser procedures, but monetization and EHR\/eye-clinic workflow integration remain question marks; pilots should target high-yield retina\/glaucoma clinics and demonstrate a measurable lift in treated cases within defined cohorts, otherwise deprioritize.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePilot: high-yield clinics\u003c\/li\u003e\n\u003cli\u003eMetric: measurable lift in treated cases\u003c\/li\u003e\n\u003cli\u003eRisk: integration and reimbursement uncertainty\u003c\/li\u003e\n\u003cli\u003eAction: park if signal equals noise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnership-driven OUS launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDistributors can cut OUS launch time by 6–12 months but typically take 20–40% channel margin, diluting control and revenue; if a partner delivers rapid access plus training and hits adoption KPIs, the initiative can move from question mark to star. Require tight milestones (quarterly\/6–12 months) with predefined exit ramps and scale only where clinical and commercial proof appears.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTime-to-market: -6–12 months\u003c\/li\u003e\n\u003cli\u003eChannel margin: 20–40%\u003c\/li\u003e\n\u003cli\u003eGovernance: quarterly milestones + exit ramps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetinal scale hinges on pivotal ≥3–6m durability to win in \u003cstrong\u003e\u0026gt;$10B\u003c\/strong\u003e market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: retinal sustained-delivery targets a \u0026gt;$10B 2024 anti-VEGF market but faces outcomes-linked payer pressure; scale only if pivotal shows durable ≥3–6m dosing and clear vision gain. Next-gen MIGS\/diagnostics must prove reproducible IOP\/diagnosis lift (WHO ~50% undiagnosed) or cut. Distributors speed OUS 6–12m but take 20–40% margin; require strict milestones.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetinal\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$10B market; target ≥3–6m durability\u003c\/td\u003e\n\u003ctd\u003eScale if pivotal OK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIGS\/Diagnostics\u003c\/td\u003e\n\u003ctd\u003eWHO ~50% undiagnosed\u003c\/td\u003e\n\u003ctd\u003ePilot; prove lift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e-6–12m; 20–40% margin\u003c\/td\u003e\n\u003ctd\u003eMilestones + exit ramps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098032509276,"sku":"glaukos-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/glaukos-bcg-matrix.png?v=1781795340","url":"https:\/\/pestel-analysis.com\/products\/glaukos-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}